Daratumumab Alone or in Combination with Lenalidomide/Dexamethasone or Pomalidomide/Dexamethasone for Relapsed/Refractory MM


Daratumumab Alone or in Combination with Lenalidomide/Dexamethasone or Pomalidomide/Dexamethasone for Relapsed/Refractory MM
Slides from presentations at ASH 2015 and transcribed comments from a recent interview with Noopur Raje, MD (2/10/16)
Usmani S et al. Clinical efficacy of daratumumab monotherapy in patients with heavily pretreated relapsed or refractory multiple myeloma. Proc ASH 2015;Abstract 29.

Plesner T et al. Daratumumab in combination with lenalidomide and dexamethasone in patients with relapsed or relapsed and refractory multiple myeloma: Updated results of a phase 1/2 study (GEN503). Proc ASH 2015;Abstract 507.

Chari A et al. Open-label, multicenter, phase 1b study of daratumumab in combination with pomalidomide and dexamethasone in patients with at least 2 lines of prior therapy and relapsed or relapsed and refractory multiple myeloma. Proc ASH 2015;Abstract 508.

Dr Raje is Director of the Center for Multiple Myeloma at Massachusetts General Hospital Cancer Center and Associate Professor of Medicine at Harvard Medical School in Boston, Massachusetts.